⚕️ Medical Disclaimer
⚕️ Medical Disclaimer: Educational discussion of published maintenance and withdrawal trials. Not a prescription to microdose compounded or branded GLP-1 drugs. Work with a licensed clinician.
Why Maintenance Is the Hard Part
Losing weight on a GLP-1 receptor agonist is only half the clinical story. The other half is what happens when exposure stops. Two opened sources frame that problem differently — and both matter.
STEP 4 (Rubino et al., JAMA 2021; PMID 33755728): after a 20-week run-in on subcutaneous semaglutide 2.4 mg (mean ~10.6% weight loss), participants were randomized to continue semaglutide or switch to placebo for 48 more weeks. Continued treatment produced further mean weight change of −7.9% from week 20 to 68; switching to placebo produced +6.9% regain over that interval (difference −14.8 percentage points).
STEP 1 extension (Wilding et al., Diabetes Obes Metab 2022): after 68 weeks of semaglutide 2.4 mg (mean ~17.3% loss in the extension subset), one year off treatment with lifestyle support withdrawn, participants regained about 11.6 percentage points — roughly two-thirds of prior weight loss — and many cardiometabolic gains drifted toward baseline.
Together those papers support a chronic-disease framing: appetite and weight set-point defense return when receptor occupancy falls. They do not automatically validate “microdosing” as an evidence-based labeled strategy.
What “Microdosing” Means in Community Practice vs Trials
Community microdosing usually means staying on a fraction of the obesity maintenance dose — for example remaining near early Wegovy escalation steps (0.25–0.5 mg weekly) after larger losses, or stretching injection intervals. That practice is widespread on forums. It is not a STEP-trial arm we opened.
STEP 4 tested full 2.4 mg continuation versus placebo — not 0.25 mg versus 2.4 mg. Do not cite STEP 4 as proof that a specific microdose maintains weight. Cite it as proof that stopping full-dose therapy after run-in allows regain relative to staying on drug.
Branded labels and clinic protocols decide titration and maintenance. Compounded “microdose” pens introduce a separate identity and quality problem.
Honest Options Clinicians Discuss (Not DIY Protocols)
• Continue the labeled maintenance dose that achieved the goal, if tolerated and covered.
• Clinician-directed slow de-escalation with monitoring — still not the same as anonymous microdosing folklore.
• Non-drug maintenance: protein intake, resistance training, sleep, and behavioral structure — necessary either way, insufficient alone for many people after large GLP-1 losses.
• Pipeline and dual-agonist options are a different conversation; see our mazdutide and pemvidutide essays for trial literacy, not substitutions.
Safety and Monitoring Notes
GI effects scale with dose and escalation speed in the class. Lower doses often mean fewer GI events — that is pharmacology, not a free pass to unsupervised self-titration.
Gallbladder disease, pancreatitis red flags, dehydration, and lean-mass loss remain class concerns at any dose. See our peptide side-effects guide and GLP-1 muscle-loss essay.
Use the CalcMyPeptide GLP-1 scheduler for labeled escalation math when you have a real pen and a clinician — not to invent a microdose chart from a research vial.
Bottom Line
Opened withdrawal and continuation trials show that semaglutide’s weight effect is exposure-dependent. Community microdosing is a hypothesis about minimum effective occupancy. Until a controlled trial tests that hypothesis at specific low doses, treat microdosing claims as anecdote layered on top of solid “don’t stop cold” evidence.